Company profile
SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tambiciclib | phase1_2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01265433 | phase2 | completed | 2010-12-21 | 2016-11-30 | Sellas Life Sciences Group | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy |
| NCT04229979 | phase3 | active_not_recruiting | 2021-02-08 | 2025-12-01 | Sellas Life Sciences Group | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |
| NCT03761914 | phase1_2 | completed | 2019-09-30 | 2022-07-05 | Sellas Life Sciences Group | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
| NCT04588922 | phase1_2 | recruiting | 2021-05-10 | 2026-12-30 | Sellas Life Sciences Group | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
| NCT01827137 | phase1_2 | completed | 2013-04-01 | 2016-12-07 | Sellas Life Sciences Group | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation |
FDA applications (0)
No records yet.